MoneyWorks4Me

Lupin shines as its arm receives USFDA approval for generic Avapro Tablets

17 Oct 2012 Evaluate

Lupin is currently trading at Rs. 562.90, up by 9.35 points or 1.32% from its previous closing of Rs. 555.55 on the BSE.

The scrip opened at Rs. 557.00 and has touched a high and low of Rs. 564.80 and Rs. 556.65 respectively. So far 1, 90,430 shares were traded on the counter.

The BSE stock of face value Rs. 2 has touched a 52 week high of Rs. 631.95 on 10-Sep-2012 and a 52 week low of Rs. 408.20 on 14-Dec-2011.

The promoters holding in the company stood at 46.89% while Institutions and Non-Institutions held 43.37% and 9.75% respectively.

Lupin’s subsidiary - Lupin Pharmaceuticals Inc. has received final approval for its Irbesartan Tablets 75mg, 150mg and 300mg from the United States Food and Drugs Administration (USFDA) to market a generic version of Sanofi Aventis US, LLC’s (Sanofi Aventis) Avapro Tablets, 75mg, 150mg and 300mg strengths.

Lupin’s Irbesartan Tablets 75mg, 150mg and 300mg are the AB-rated generic equivalent of Sanofi Aventis’s Avapro Tablets. Irbesartan is an angiotensin II receptor antagonist and is indicated for the treatment of Hypertension and Nephropathy in Type 2 Diabetic patients. Avapro Tablets had annual US sales of approximately $400.7 million (IMS MAT June 2012 sales).

Lupin has a vibrant presence in the Indian pharmaceuticals market and has over the past several years made major strides in expanding its therapy portfolio. The company has a robust promotion and distribution setup along with a strong presence in various therapeutic areas, including the fast growing diabetes market.

Lupin Share Price

2235.00 -26.00 (-1.15%)
14-Aug-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1924.90
Dr. Reddys Labs. 1202.00
Cipla 1450.00
Lupin 2235.00
Zydus Lifesciences 1140.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: